Investigational pharmacologic treatment for liver disease.
Liver disease can cause significant morbidity and mortality. Few pharmacological options exist for these diseases, however, new agents are in development and older agents are being evaluated for new indications. Several new nucleoside and nucleotide analogues are being developed to treat hepatitis B virus infection. Pegylated interferons have been developed for hepatitis C infection. Ursodeoxycholic acid has recently been implicated in the treatment of liver disease, including non-alcoholic steatohepatitis and primary sclerosing cholangitis.
Siatkosky
Lori L
LL
Department of Pharmacy, Spectrum Health, Grand Rapids, MI, USA.
Shermock
Kenneth M
KM
Younossi
Zobair M
ZM
D000818:Animals; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D015507:Drugs, Investigational / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008107:Liver Diseases / Q000188:drug therapy* / Q000378:metabolism; D013678:Technology, Pharmaceutical / Q000379:methods*
D015507:Drugs, Investigational